Cambridge Healthtech Institute’s 7th Annual
January 21-22, 2020
Part of the Antibody Therapeutics pipeline
Antibody-Drug Conjugates have demonstrated their ability to deliver cytotoxic small-molecule drugs through a selective and targeted mechanism in the fight against cancer. In recent years, ADCs have entered almost 600 clinical trials with more than 60 distinct ADC molecules currently under development. Despite the enormous promise, a low therapeutic index has plagued ADC development, particularly for treating solid tumors.
Cambridge Healthtech Institute’s Antibody-Drug Conjugates conference explores the engineering finesse required to achieve the crucial balance between efficacy and safety, thus leading the way to more potent and targeted molecules. Case studies and data will be shared that illustrate the ongoing efforts to engineer ADCs, move them into the clinic, and conquer cancer.
ADCs FOR IMMUNOTHERAPY: A WINDING PATH
KEYNOTE PRESENTATION: Learnings from Successes and Failures of ADCs and Cancer Immunotherapies
Rakesh Dixit, PhD, DABT, President & CEO, Bionavigen, LLC
Antibody-Drug Conjugates for Immunology (iADC)
Adrian Hobson, PhD, Research Fellow, Global Biologics - Antibody Drug Conjugates, AbbVie Bioresearch Center, AbbVie
NAVIGATING THE PROMISE OF ADCs
Antibody-Drug Conjugates: Progress, Pitfalls, and Promises
Mark Glassy, PhD, Chairman, Nascent Biotech, Inc.
Antibody-Drug Conjugates as Targeted Conditioning Agents for Bone Marrow Transplant Patients
Bradley Pearse, PhD, Director, Biotherapeutics, Magenta Therapeutics
TARGETING TUMORS WITH ADCs
Improved Tumor Growth Inhibition of Diabody-Drug Conjugates Achieved by Half-Life Extension
Qing Li, PhD, Scientist, Antibody Discovery & Protein Engineering, AstraZeneca plc
Optimal Design, Anti-Tumor Efficacy, and Tolerability of Anti-CXCR4 Antibody-Drug Conjugates
Maria J. Costa, PhD, Associate Director, Research, Immune Onc Therapeutics, Inc.
INNOVATING ADC ENGINEERING
Probody Therapeutics in the Treatment of Cancer
Siew Schleyer, PhD, Director, Oncology Research, Cytomx Therapeutics
Amanitin-Based Antibody-Drug Conjugates as New Therapeutic Modalities for Cancer Therapy
George Octavian Badescu, PhD, Vice President, Scientific Affairs, Heidelberg Pharma AG
Peptide Nucleic Acid (PNA)-Mediated Pretargeting for Radionuclide Therapy
Amelie Eriksson Karlström, PhD, Professor, Protein Sciences, Engineering Sciences in Chemistry, Biotechnology and Health, KTH Royal Institute of Technology
* The program is subject to change without notice, due to unforeseen reason.
2020 Conferences & Training Seminars